Conventional vaccines, also known as traditional or inactivated vaccines, represent a widely used and effective approach to immunization. These vaccines utilize either weakened or killed forms of the targeted pathogen, such as viruses or bacteria, to stimulate an immune response without causing the disease. Inactivated vaccines typically involve using heat, chemicals, or radiation to deactivate the infectious agent while preserving its immunogenic properties. Live attenuated vaccines use weakened forms of the pathogen, rendering them less virulent but still capable of eliciting a robust immune response. Examples of conventional vaccines include those against diseases like influenza, polio, hepatitis A and B, and pertussis. These vaccines have been instrumental in controlling and preventing a range of infectious diseases, contributing significantly to public health. Conventional vaccines have some limitations, such as the need for cold storage for certain types and the potential for reversion to virulence in live attenuated vaccines. However, ongoing research and advancements continue to optimize these vaccines and explore new technologies for vaccine development. They remain a cornerstone of global vaccination efforts, providing essential protection against a variety of infectious diseases.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States